Author

S. J. Strauss

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

G. Zoumpoulidou· 2 shared S. Mittnacht· 2 shared C. A. Mendoza· 1 shared C. Alvarez-Mendoza· 1 shared C. D. Steele· 1 shared C. Mancusi· 1 shared J. Manji· 1 shared K. Tomita· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Zoumpoulidou

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Therapeutic vulnerability to PARP1/2 inhibition in RB1-mutant osteosarcoma

G. Zoumpoulidou, C. A. Mendoza, C. Mancusi, R. M. Ahmed, M. Denman, C. D. Steele, J. Manji, N. Pillay, S. J. Strauss, S. Mittnacht

This study shows RB1-mutant osteosarcoma is hypersensitive to PARP1/2 inhibitors, with sensitivity linked to replication checkpoint activation rather than homologous repair defects.

bioRxiv · Dec 28, 2020 · PreprintCancer Biology

Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by ATR Inhibitors

T. Goncalves, G. Zoumpoulidou, C. Alvarez-Mendoza, L. C. Collopy, S. J. Strauss, S. Mittnacht, K. Tomita

This study identifies that osteosarcoma cell lines with short telomeres are selectively sensitive to ATR inhibitors, suggesting telomere length as a predictor of drug response.

bioRxiv · Aug 18, 2020Cancer Biology